Table 2 Stepwise Cox regression analyses for prognostic factors.

From: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

 

Reference

HR (95% CI)

p value

Progression-free survival

 Time to relapse: 3–6 months

≥6 months

1.65 (1.17–2.33)

0.004

 RDI: < 85%

≥85%

1.48 (1.05–2.09)

0.024

Overall survival

 Treatment type: belotecan

Topotecan

0.69 (0.48–0.99)

0.045

 Time to relapse: 3–6 months

≥6 months

2.07 (1.42–3.03)

0.0002

 ECOG PS: 1

0

1.36 (0.83–2.22)

0.22

 ECOG PS: 2

0

7.22 (2.05–25.4)

0.002a

 Baseline Hb: < 12 g/dL

≥12 g/dL

1.54 (1.05–2.26)

0.028

 Baseline Hb: <12 g/dL_LD

≥12 g/dL_LD

1.87 (0.82–4.25)

0.13b

 Baseline Hb: <12 g/dL_ED

≥12 g/dL_ED

1.64 (1.08–2.47)

0.018b

  1. ECOG PS Eastern Cooperative Oncology Group performance status, Hb haemoglobin.
  2. aOnly three patients had an ECOG PS of 2.
  3. bp values were calculated using stratified Cox regression analysis.
Back to article page